新型靶向化合物——植物大麻素的生物合成途径及 研究进展

植物大麻素是具有生物活性的一系列萜类化合物的总称,被认为是大麻的专有成分。具有主要药理活性的植物大麻素为Δ~9-四氢大麻酚(Δ~9-tetrahydrocannabinol,Δ~9-THC)和大麻二酚(Cannabidiol,CBD),均以内源性大麻素受体为靶点,通过激活内源性大麻素系统而参与人体许多生理病理过程,具有广泛的治疗潜力。目前,Δ~9-THC、CBD及其类似物或组合制剂,已用于治疗癫痫、癌症化疗患者的呕吐、多发性硬化症痉挛和缓解神经性疼痛以及晚期癌症患者的疼痛。随着对Δ~9-THC和CBD应用价值的深度发掘和药用标准化制剂需求量增加,Δ~9-THC和CBD在制药工业中实现规模化生产迫在眉睫。通过综述近年来植物大麻素的药理学研究进展,植物大麻素生物合成途径和关键酶的作用机制以及制药工业中植物大麻素的生产策略,旨在探索利用合成生物学技术解决植物大麻素药源问题的潜力,为合成大麻素的微生物工程研发提供理论基础,促进药用大麻素的规模化生产。     

新疆洋海古代大麻叶的大麻酚分析(英文)

为了检测新疆吐鲁番地区洋海古墓中2500年前大麻叶中两个大麻酚:四氢大麻酚(THC)与大麻二酚(CBD),采用高压液相分析技术(HPLC)测定26.716 g大麻叶中THC与CBD的含量分别为0.2928 mg与0.2830 mg,占叶重量的(0.110%)%与(0.106%)%。THC与CBD标准品从现代大麻叶中分离得到,通过波谱分析鉴定。     

火麻叶中大麻二酚提取工艺的响应面法优化及不同部位含量分布

本文研究一种超声波辅助提取火麻叶中大麻二酚(cannabidiol, CBD)的方法,同时分析火麻不同部位的CBD含量。首先建立CBD的HPLC检测方法,采用单因素实验确定超声提取功率、提取温度、提取时间、料液比4个因素对火麻叶中CBD提取率的影响;利用Design-expert软件进行Box-Benhnken实验设计确定并验证CBD的超声辅助提取的最优工艺条件,并检测火麻不同部位CBD含量。实验表明：采用Agilent HC-C₁₈柱(250 mm×4.6 mm, 5μm),检测波长：220 nm,流速：1.0 mL/min,柱温：28℃,流动相：甲醇-水=90∶10,等度洗脱,在此条件下的分离效果和峰型较好,并且结果准确可靠,稳定性好。以甲醇为提取溶剂,最佳提取工艺条件为：提取功率320 W,提取温度81℃,提取时间26 min,料液比1∶22 g/mL,在此条件下得到CBD含量的平均值为79.53±0.26 mg/g。火麻嫩叶中CBD含量最高,其余依次为老叶、种子和茎,根中含量最低。结果表明,超声波提取是一种高效的大麻二酚提取方法,且作为一种天然产物资源,大...     

滇南农家大麻品种中大麻素化学型及基因型研究

以1个滇南农家大麻品种群体为研究对象,通过化学分析及同源克隆方法,研究了21个单株中2种主要大麻素——四氢大麻酚(THC)和大麻二酚(CBD)的化学型和基因型,以揭示大麻素含量、化学型以及基因型三者之间的关系,为工业大麻新品种选育提供理论依据。研究表明:(1)化学检测结果显示,21个单株均含有THC,THC含量在0.07%~1.35%之间,其中7个单株仅含THC,5个单株含THC和微量CBD,9个单株同时含有THC和CBD,CBD含量范围为0~0.58%。(2)CBD/THC比值显示,该群体仅存在毒品型和中间型2种化学型,且中间型大麻中THC和CBD含量显著正相关。(3)基因扩增及测序分析结果显示,该群体为基因型杂合群体,群体内THCA合成酶基因存在5个变异位点,CBDA合成酶基因存在2个变异位点,但变异位点和THC及CBD的含量无直接关系。(4)群体内单株的基因型和化学型完全对应,且THCA合成酶基因及CBDA合成酶基因可作为分子标记来鉴定单株化学型。     

大麻种质资源中大麻素化学型及基因型鉴定与评价

大麻素(cannabinoids)是大麻植物中特有的次生代谢产物,主要成分为四氢大麻酚(THC,tetrahydrocannabinol)和大麻二酚(CBD,cannabidiol)。本研究通过对我国不同来源地的23份大麻种质资源共69个单株材料中THC和CBD含量特征及其合成关键酶基因多态性进行分析,鉴定了我国大麻种质资源的大麻素化学型及基因型。结果显示,69个单株中大麻素含量差异显著,THC含量均值为0.56%,范围为0.01%~2.45%;CBD含量均值为0.53%,范围为0~2.24%;根据CBD/THC含量比值,大麻资源可划分为毒品型(占44.93%)、中间型(占20.29%)和纤维型(占34.78%)3种大麻素化学型,毒品型、中间型中分别有93.5%和71.4%的植株中THC含量0.3%,纤维型植株中THC含量≤0.08%。3种化学型遗传位点(共显性位点B)的基因型分别为BT/BT、BT/BD和BD/BD;BT等位基因(THCAS)存在10个变异位点,氨基酸序列有4处变异,BD等位基因(CBDAS)存在4个变异位点,均为同义突变。根据THCAS和CBDAS基因多态性,设计了一个共显性复合PCR分子标记,可准确鉴定出大麻3种化学型。研究结果揭示了我国大麻种质资源中大麻素含量、化学型和基因型三者之间的关系,可为大麻素遗传研究与利用提供理论依据。     

花生四烯乙醇胺的研究进展

花生四烯乙醇胺（arachidonoylethanolamide,anandamide,ANA）是近年来确定的大麻素受体的内源性配基,它主要分布在中枢神经系统、免疫系统及子宫等部位,具有大麻的主要活性成分--Δ9-四氢大麻酚（Δ9-THC）的药理功能.ANA有两种受体,即脑型受体（CB1）和脾型受体（CB2）,它们都是与GTP偶联的跨膜受体,是ANA发挥作用的主要途径.脂肪酸酰胺水解酶（fattyacidamidehydrolase,FAAH）是ANA特异性极高的水解酶,它可以迅速调节ANA在体内的含量,从而发挥特异的生理作用.     

花生四烯乙醇胺的研究进展

花生四烯乙醇胺（arachidonoylethanolamide, anandamide，ANA）是近年来确定的大麻素受体的内源性配基，它主要分布在中枢神经系统、免疫系统及子宫等部位，具有大麻的主要活性成分——Δ⁹-四氢大麻酚（Δ⁹-THC）的药理功能.ANA有两种受体，即脑型受体（CB1）和脾型受体（CB2），它们都是与GTP偶联的跨膜受体，是ANA发挥作用的主要途径.脂肪酸酰胺水解酶（fatty acid amide hydrolase，FAAH）是ANA特异性极高的水解酶，它可以迅速调节ANA在体内的含量，从而发挥特异的生理作用.     

符合大肠癌早期无创分子诊断要求的粪便DNA样本贮存条件考察

目的:考察在不同温度下储存时间和反复冻融对粪便中人基因组DNA含量的影响。方法:1.将粪便样本在室温、4℃、-40℃和-70℃条件下分别放置不同时间和-40℃条件下保存并反复冻融后,使用QIAamp DNA Stool Mini Kit试剂盒提取得到粪便DNA,通过实时荧光定量PCR体系对人KRAS基因定量确定人基因组DNA含量,评价粪便样本不同冻存条件对其中人基因组DNA含量的影响。2.将粪便DNA样本在4℃和-40℃条件下分别放置不同时间和-40℃条件下保存并反复冻融后,评价粪便DNA样本不同冻存条件下对其中人基因组DNA含量的影响。结果:1).粪便样本常温放置2小时,其中人基因组DNA即发生明显降解(P0.01),4℃可保存3天左右,-40℃可保存4周,-70℃可保存3个月以上,粪便反复冻融第3次,其中人基因组DNA降解具有统计学意义(P0.05)。2).粪便DNA 4℃可保存3天,-40℃可保存4周,粪便DNA反复冻融第4次,其中人基因组DNA降解具有统计学意义(P0.05)。结论:符合大肠癌早期无创分子诊断要求的粪便DNA贮存条件:粪便样本室温收集后尽快保存;短期可处理的粪便样本存放在4℃条件下(3天内);暂无法处理则存于-40℃(1个月内);粪便样本长期保存在-70℃条件下,可保存3个月。     

四川王朗自然保护区缺苞箭竹（Fargesia denudate Yi.）总酚含量及变化规律

采用分光光度法对四川王朗自然保护区缺苞箭竹的总酚含量进行了分析,结果表明:在采集到的不同器官中均有酚类物质分布,总酚含量最高的为叶龄超过1a的老叶(2.05%),笋中的总酚含量最低(0.20%).海拔高度和日照强度在一定程度上影响其含量变化,在海拔高和光照强的条件下,幼嫩器官中的总酚含量有明显增加的趋势.研究分析了缺苞箭竹各器官总酚含量的变化规律,及其与环境因子和大熊猫采食量之间的关系.     

不同切制条件对大黄饮片中蒽醌化合物含量的影响

目的:采用高效液相色谱法比较不同的大黄切制条件对蒽醌类化合物含量的影响.方法:以大黄素和大黄酚为对照品,采用Merck C18色谱柱(4.6 mm×250 mm,5μm),甲醇-水-磷酸(体积比78.7:20.9:0.4)为流动相,检测波长254 nm,外标法测定了不同切制条件下得到的18份饮片样品中游离和结合型大黄素和大黄酚的含量.结果:从18份样品测定的平均值来看,游离型大黄素和大黄酚的含量为8.69 mg/g,结合型的为4.45 mg/g.从切制条件来看,薄片、中片、厚片总蒽醌(即游离型和结合型大黄素和大黄酚之和)含量平均分别为13.47、13.33和12.6mg/g;60℃干燥10.5 h、80℃干燥6.5 h和100℃干燥4 h,其总蒽醌含量平均分别为13.73、12.86和12.8 mg/g.结论:大黄类饮片切制的适宜条件为薄片或中片,60℃干燥10.5 h.     

Innovative development and validation of an HPLC/DAD method for the qualitative and quantitative determination of major cannabinoids in cannabis plant material

GC is commonly used for the analysis of cannabis samples, e.g. in forensic chemistry. However, as this method is based on heating of the sample, acidic forms of cannabinoids are decarboxylated into their neutral counterparts. Conversely, HPLC permits the determination of the original composition of plant cannabinoids by direct analysis. Several HPLC methods have been described in the literature, but most of them failed to separate efficiently all the cannabinoids or were not validated according to general guidelines. By use of an innovative methodology for modelling chromatographic responses, a simple and accurate HPLC/DAD method was developed for the quantification of major neutral and acidic cannabinoids present in cannabis plant material: Δ9-tetrahydrocannabinol (THC), THC acid (THCA), cannabidiol (CBD), CBD acid (CBDA), cannabigerol (CBG), CBG acid (CBGA) and cannabinol (CBN). Δ8-Tetrahydrocannabinol (Δ8-THC) was determined qualitatively. Following the practice of design of experiments, predictive multilinear models were developed and used in order to find optimal chromatographic analytical conditions. The method was validated following an approach using accuracy profiles based on β-expectation tolerance intervals for the total error measurement, and assessing the measurements uncertainty. This analytical method can be used for diverse applications, e.g. plant phenotype determination, evaluation of psychoactive potency and control of material quality.     

Anticonvulsant properties of delta 9-tetrahydrocannabinol and other cannabinoids

Anticonvulsant doses of Δ⁹-tetrahydrocannabinol (Δ⁹-THC) markedly lower body temperature in mice at an ambient temperature of 22°C, but there is little such effect at 30°C. The anticonvulsant properties of Δ⁹-THC are as follows: The drug abolishes hind-limb extension in a maximal electroshock (MES) test, elevates both the MES (extensor) and 6-Hz-electroshock thresholds, exerts no effect on the 60-Hz-electroshock threshold, and enhances minimal seizures caused by pentylenetetrazol. All anticonvulsant properties studied, with the exception of the 60-Hz-electroshock threshold, were unaffected by the hypothermia resulting at 22°C. Additional experiments with Δ⁹-THC indicated that chronic treatment results in the development of tolerance, as determined by the MES test with rats. The four principal naturally occurring cannabinoids, Δ⁹-THC, Δ⁸-THC, cannabinol and cannabidiol, display anticonvulsant activity, as does the major, primary metabolite of Δ⁹-THC, 11-hydroxy-Δ⁹-THC. Of all agents investigated in mice, the synthetic cannabinoids, dimethylheptylpyran and its isomers, are the most potent anticonvulsants. The results of a study of the relative motor toxicity and anticonvulsant activity of the cannabinoids demonstrate that these properties are at least partially separable among the various agents.     

Seasonal fluctuations in cannabinoid content of Kansas Marijuana

Marijuana (Cannabis sativa L.) was sampled at nine progressive growth stages in Riley County, Kansas, and analyzed for four major cannabinoids: cannabidiol (CBD), della-8-tetrahydrocannabinol (delta-8-THC), delta-9-tetrahydrocannabinol (delta-9-THC), and cannabinol (CBN). Seasonal fluctuation in cannabinoids were related to stage of plant development. Cannabinoids were lowest in seedlings, highest prior to flowering and at an intermediate level thereafter until physiological maturity. Cannabinoids were highest in flowers and progressively lower in leaves, petioles, stems, seeds, and roots. Cannabinoid content of male and female flowers was not significantly different. Cannabidiol occurred in the highest concentrations (0.01 to 0.94% of dry matter) in all plant parts; delta-9-THC, the next highest (0.0001 to 0.06%) in the study over time. Cannabidiol content of leaf tissue of plants sampled from ten locations at flowering, ranged from 0.12 to 1.7%; delta-9-THC, from 0.01 to 0.49%. Some variation was attributed to environmental factors. Results indicate transformation of CBD to delta-9-THC to CBN. Environmental stress apparently increased delta-9-THC concentration, and bivalent ions: Mg, Mn, and Fe of leaf tissue could have regulated enzyme systems responsible for cannabinoid synthesis.     

Hydroxylation and glycosylation of Δ9-tetrahydrocannabinol by Catharanthus roseus cell suspension culture

Δ⁹-tetrahydrocannabinol is the active constituent in Cannabis sativa, with reported analgesic, anti-emetic, anti-oxidative, neuroprotective, and anti-inflammatory activities. Δ⁹-THC has been used to treat a number of disease states including pain, anxiety, asthma, glaucoma, and hypertension. Poor water solubility of Δ⁹-THC greatly reduces its clinical effectiveness. Consequently, there is a need to modify the compound to increase its polarity and pharmaceutical efficacy. The aim of this study was to test the capability of Catharanthus roseus suspension cultured cells to convert Δ⁹-THC into more polar derivatives. The transformed metabolites were analyzed and isolated by HPLC. Structures of some new derivatives were proposed on the basis of molecular ion peaks and fragmentation patterns obtained from LC-MS and UV spectra obtained by HPLC, respectively. Δ⁹-THC was rapidly absorbed by Catharanthus roseus cultured cells and upon biotransformation new glycosylated and hydroxylated derivatives were isolated by preparative HPLC. In addition, cannabinol was detected as degradation product, including its glycosylated derivative. Based on these results, it is concluded that Catharanthus cultured cells have great potential to transform Δ⁹-THC into more polar derivatives and can be used for the large scale production of new cannabinoids, which can be a source of new compounds with interesting pharmacological profiles.     

Anticoagulant effects of a Cannabis extract in an obese rat model

Blood coagulation studies were conducted to determine the possible anti-/prothrombotic effect of an organic cannabis extract and the three major cannabinoids, THC, CBD and CBN. The in vitro effect of the cannabis extract on thrombin activity produced an IC50 value of 9.89 mg/ml, compared to THC at 1.79 mg/ml. It was also found that the extract, THC and CBN showed considerable inhibition of thrombin-induced clot formation in vitro with IC50 values of 600, 87 and 83 microg/ml for the extract, THC and CBN respectively. In an in vivo model used to determine clotting times of lean and obese rats treated with a cannabis extract, 50% clotting times were found to be 1.5 and 2 fold greater than their respective control groups, supporting the results obtained in the in vitro model. The study thus shows that Cannabis sativa and the cannabinoids, THC and CBN, display anticoagulant activity and may be useful in the treatment of diseases such as type 2 diabetes in which a hypercoagulable state exists.     

A qualitative and quantitative HPTLC densitometry method for the analysis of cannabinoids in Cannabis sativa L.

Introduction – Cannabis and cannabinoid based medicines are currently under serious investigation for legitimate development as medicinal agents, necessitating new low‐cost, high‐throughput analytical methods for quality control. Objective – The goal of this study was to develop and validate, according to ICH guidelines, a simple rapid HPTLC method for the quantification of Δ⁹‐tetrahydrocannabinol (Δ⁹‐THC) and qualitative analysis of other main neutral cannabinoids found in cannabis. Methodology – The method was developed and validated with the use of pure cannabinoid reference standards and two medicinal cannabis cultivars. Accuracy was determined by comparing results obtained from the HTPLC method with those obtained from a validated HPLC method. Results – Δ⁹‐THC gives linear calibration curves in the range of 50–500 ng at 206 nm with a linear regression of y = 11.858x + 125.99 and r² = 0.9968. Conclusion – Results have shown that the HPTLC method is reproducible and accurate for the quantification of Δ⁹‐THC in cannabis. The method is also useful for the qualitative screening of the main neutral cannabinoids found in cannabis cultivars. Copyright © 2009 John Wiley & Sons, Ltd.     

Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: role of phenolic hydroxyl groups in the resorcinol moiety

AimsIn this study, we examined the inhibitory effects of Δ⁹-tetrahydrocannabinol (Δ⁹-THC), cannabidiol (CBD), and cannabinol (CBN), the three major cannabinoids, on the activity of human cytochrome P450 (CYP) 3A enzymes. Furthermore, we investigated the kinetics and structural requirement for the inhibitory effect of CBD on the CYP3A activity.Main methodsDiltiazem N-demethylase activity of recombinant CYP3A4, CYP3A5, CYP3A7, and human liver microsomes (HLMs) in the presence of cannabinoids was determined.Key findingsAmong the three major cannabinoids, CBD most potently inhibited CYP3A4 and CYP3A5 (IC₅₀ = 11.7 and 1.65 μM, respectively). The IC₅₀ values of Δ⁹-THC and CBN for CYP3A4 and CYP3A5 were higher than 35 μM. For CYP3A7, Δ⁹-THC, CBD, and CBN inhibited the activity to a similar extent (IC₅₀ = 23–31 μM). CBD competitively inhibited the activity of CYP3A4, CYP3A5, and HLMs (K_i = 1.00, 0.195, and 6.14 μM, respectively). On the other hand, CBD inhibited the CYP3A7 activity in a mixed manner (K_i = 12.3 μM). Olivetol partially inhibited all the CYP3A isoforms tested, whereas d-limonene showed lack of inhibition. The lesser inhibitory effects of monomethyl and dimethyl ethers of CBD indicated that the ability of CYP3A inhibition by the cannabinoid attenuated with the number of methylation on the phenolic hydroxyl groups in the resorcinol moiety.SignificanceThis study indicated that CBD most potently inhibited catalytic activity of human CYP3A enzymes, especially CYP3A4 and CYP3A5. These results suggest that two phenolic hydroxyl groups in the resorcinol moiety of CBD may play an important role in the CYP3A inhibition.     

Interactions of cannabinoids with bovine serum albumin

There is no shift of emission maximum (F₄₇₀nm) of bovine serum albumin (BSA)-l-anilino-8-naphthatene sulphonic acid (ANS) complex in the pesence of delta-9-tetrahydrocannabinol (delta-9-THC) alone and cannabidiol (CBD) or cannabinol (CBN) in the presence and absence of delta-9-THC. Delta-9-THC (1.66–13.33 M) and CBD at higher concentrations (13.33–20.0 M) produce a concentration-dependent significant quenching of fluorescence of BSA-ANS complex, but CBN (l.66–20.0 M) as well as CBD at lower concentrations (1.66–6.66 M) fails to produce any significant change in Iluorescence intensity under similar conditions. Furthermore, neither CBD nor CBN is able to affect the delta-9-THC-induced quenching of fluorescence intensity of BSA-ANS complex. These results indicate that the binding of cannabinoids to the ANS binding sites of BSA molecule are in the order detta-9-THC > CBr3 > CBN, and CBD or CBN does not have any influence on the binding of delta-9-THC to BSA molecules under these conditions.     

Le nouveau paysage du cannabis II. Données récentes sur la psychotoxicité du cannabis

After delta-9-tetrahydrocannabinol (Δ9-THC) has supported the anandamidergic tone, thereby increasing its anxiolytic and antidepressant effects, it loses its efficacy in this respect. Anxious and/or depressive troubles which could have prompted the abuse of cannabis then reappear more intensely. They peak when consumption is completely stopped. Cannabis consumption may contribute to polydrug abuse. Its association with tobacco makes it more difficult to give up both substances of abuse. Cannabis use encourages the consumption of alcohol and this association is especially deleterious as regards car accidents. Δ9-THC sensitises cannabis abusers to perceive the appetitive effects of heroin in a more acute manner. Cannabis consumption also makes withdrawal symptoms associated with heroin abuse more severe. Cannabis appears to be able to reveal schizophrenia in patients bearing a neurobiological vulnerability substratum to this disease. It seems especially appreciated by people suffering of negative symptoms of schizophrenia, which could prompt them to abuse cannabis, and then triggering the positive symptoms of the disease. These positive symptoms are particularly resistant to treatment with antipsychotic medication when cannabis abuse is continued. All this recent data necessitates extreme care with this drug of abuse, whose dangerous effects are becoming more and more known.     

Hypothermic action of delta 9-tetrahydrocannabinol, 11-hydroxy-delta 9-tetrahydrocannabinol and 11-hydroxy-delta 8-tetrahydrocannabinol in mice

The hypothermic activity of Δ⁹-tetrahydrocannabinol (Δ⁹-THC), a metabolite, 11-hydroxy-Δ⁹-tetrahydrocannabinol (11-OH-Δ⁹-THC) and 11-hydroxy-Δ⁸-tetrahydrocannabinol (11-OH-Δ⁸-THC) has been determined in male mice maintained at an ambient temperature of 20 ± 1°C. The mean body temperature of mice that received 2, 4, 16 or 32 mg/kg, i. v., of a tetrahydrocannabinol was significantly lower than that of vehicle treated mice (p <0.05) within 2 minutes after drug administration. Dose-response relationships show the intrinsic activity of Δ⁹-THC to be significantly greater than that of 11-OH-Δ⁹-THC or 11-OH-Δ⁸-THC in this system (p <0.05). The data indicate that the hypothermic activity of Δ⁹-THC cannot be explained entirely by metabolism to 11-OH-Δ⁹-THC.